Bispecific CAR T Cell Therapy Targeting BCMA and CD19 in Relapsed/Refractory Multiple Myeloma: A Phase I/II Clinical Trial

Bispecific CAR T Cell Therapy Targeting BCMA and CD19 in Relapsed/Refractory Multiple Myeloma: A Phase I/II Clinical Trial

In the evolving landscape of hematology and oncology, innovative treatments for challenging conditions like relapsed or refractory multiple myeloma (R/R MM) are of paramount importance. It is in this context that the recent phase I/II, open-label study investigating the efficacy of bispecific CAR-T cell therapy targeting BCMA and CD19 comes to light, marking a significant advancement in the therapeutic domain. This study, meticulously carried out by a dedicated team of researchers led by Professor Kailin Xu from the Department of Hematology at The Affiliated Hospital of Xuzhou Medical University, alongside esteemed colleagues from various prestigious institutions across China, has been a beacon of hope for patients grappling with this relentless malignancy. The findings of this groundbreaking research were meticulously documented, underscoring not only the potential of bispecific BC19 CAR T cells as a viable treatment option but also the collaborative effort and expertise that epitomizes the spirit of innovation in the field. This endeavor, emblematic of the strides being made in hematology research, was brilliantly showcased during a session at a renowned medical conference, an event that has become a cornerstone for the dissemination of cutting-edge scientific knowledge and clinical practices.
EAU24 Expert Commentary丨Professor Tongyi Men: Bringing More Hope to Kidney Cancer Patients Through the Latest Research Advances

EAU24 Expert Commentary丨Professor Tongyi Men: Bringing More Hope to Kidney Cancer Patients Through the Latest Research Advances

The situation of urological tumors in China is not optimistic, with the incidence of kidney cancer increasing annually by 4% to 7%. There is an urgent need to explore new diagnostic and therapeutic strategies to improve incidence rates and patient prognosis. The 39th Annual Congress of the European Association of Urology (EAU24) was held from April 5 to 8, 2024, in Paris, France. Oncology Frontier invited Professor Tongyi Men from the Affiliated Hospital of Inner Mongolia Medical University to share his insights from the conference and advancements in kidney cancer research.
2024 South-North Forum | Prof. Zhiming Shao: Breast Cancer Treatment in the Era of Precision Typing

2024 South-North Forum | Prof. Zhiming Shao: Breast Cancer Treatment in the Era of Precision Typing

Breast diseases have the highest incidence among women, with breast cancer being the leading malignant tumor threatening women's health. From "one-size-fits-all" treatments to "individualized therapy" based on patients, the exploration of breast cancer treatment has been ongoing for centuries. At the 2024 South-North Forum, Prof. Zhiming Shao from Fudan University Cancer Hospital presented a report titled "Precision Typing Drives Diagnosis and Treatment Innovation: A New Model for Breast Cancer Precision Diagnosis and Treatment." This article introduces the key points of the report.

Multiparametric MRI Differentiates Small Hepatocellular Carcinoma (<3 cm) from Benign Liver Lesions Associated with Budd-Chiari Syndrome

The “International Liver Disease - Hepatic Vascular Disease Column” is an academic column initiated by Dr. Xingshun Qi from the Department of Gastroenterology at General Hospital of Northern Theater Command, in collaboration with the editorial team of International Liver Disease. This column regularly collects and organizes research progress in the field of hepatic vascular diseases, selecting an important literature piece for detailed discussion every two weeks (Wednesday). The aim is to help readers understand the underlying mechanisms, inspire clinical research thinking, and apply knowledge effectively.
High Frequency of Type 3 Dendritic Cells in CD1c+DCs on Day 28 Post-Allo-HSCT as a Potential Marker for Severe GVHD in Pediatric Patients

High Frequency of Type 3 Dendritic Cells in CD1c+DCs on Day 28 Post-Allo-HSCT as a Potential Marker for Severe GVHD in Pediatric Patients

llogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Chimeric Antigen Receptor T-cell (CAR-T) therapy have become crucial in the treatment of leukemia. However, the effectiveness and safety of these treatments continue to be hot topics of research. Recent breakthrough studies have provided valuable insights, particularly in the treatment of children with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), prevention and monitoring of graft-versus-host disease (GVHD), and management of complications following CAR-T therapy. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting, held from April 14 to 17, 2024, in Glasgow, UK, focused on the latest advancements in stem cell transplantation and cellular therapy, pushing forward better clinical outcomes for hematologic patients. At this conference, Professor Shaoyan Hu and her team from the Affiliated Children's Hospital of Soochow University reported on six studies. Oncology Frontier - Hematology Frontier specially invited Professor Shaoyan Hu and her team members to share their research findings on the efficacy and safety of allo-HSCT and CAR-T cell therapy in pediatric leukemia patients in a roundtable discussion format and to provide insightful commentary on these six studies.
2024 CSCO Guidelines Conference | Prof. Yao Zhu: Combining the Latest Research to Guide Prostate Cancer Treatment Guidelines for Patient Protection

2024 CSCO Guidelines Conference | Prof. Yao Zhu: Combining the Latest Research to Guide Prostate Cancer Treatment Guidelines for Patient Protection

Prostate cancer is a malignant tumor occurring in the male reproductive system. Although the incidence in China is lower than in Western countries, it has rapidly increased in recent years, now ranking as the sixth most common male malignancy. With rapid advances in related research, updating prostate cancer treatment guidelines based on the latest evidence-based medicine to suit China's specific context is crucial for early diagnosis, treatment, and improving prognosis. The 2024 CSCO Guidelines Conference is about to take place. "Oncology Frontier" invited Prof. Yao Zhu from Fudan University Cancer Hospital to share key points of the guideline updates.
2024 South-North Forum | Prof. Xiaowei Qi: Advancements in Dual Target Neoadjuvant Therapy for HER2-Positive Breast Cancer

2024 South-North Forum | Prof. Xiaowei Qi: Advancements in Dual Target Neoadjuvant Therapy for HER2-Positive Breast Cancer

In the first-line treatment of advanced HER2-positive breast cancer, the combination of pyrotinib and trastuzumab has introduced a new therapeutic model. The complementary mechanisms of large and small molecules have achieved a median progression-free survival (mPFS) of 24.3 months, setting a new standard for first-line treatment of advanced HER2-positive breast cancer. This combination therapy is now recommended by three major domestic guidelines: CSCO BC, CBCS, and ABCC. While the success of this dual-target regimen in advanced stages is clear, its effectiveness in early-stage treatment remains to be seen. Can it provide a new dual-target option for neoadjuvant therapy in HER2-positive breast cancer? In this issue, "Oncology Frontier" invites Prof. Xiaowei Qi to share insights from his report at the South-North Forum titled "Clinical and Translational Research on Pyrotinib Combined with Trastuzumab as Neoadjuvant Therapy for HER2-Positive Breast Cancer," offering an in-depth exploration of this new dual-target regimen in early anti-HER2 therapy.
EBMT Roundtable Discussion | Professor Shaoyan Hu’s Team: Efficacy and Safety of Allo-HSCT and CAR-T Cell Therapy in Pediatric Leukemia Patients

EBMT Roundtable Discussion | Professor Shaoyan Hu’s Team: Efficacy and Safety of Allo-HSCT and CAR-T Cell Therapy in Pediatric Leukemia Patients

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Chimeric Antigen Receptor T-cell (CAR-T) therapy have become crucial in the treatment of leukemia. However, the effectiveness and safety of these treatments continue to be hot topics of research. Recent breakthrough studies have provided valuable insights, particularly in the treatment of children with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), prevention and monitoring of graft-versus-host disease (GVHD), and management of complications following CAR-T therapy. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting, held from April 14 to 17, 2024, in Glasgow, UK, focused on the latest advancements in stem cell transplantation and cellular therapy, pushing forward better clinical outcomes for hematologic patients. At this conference, Professor Shaoyan Hu and her team from the Affiliated Children's Hospital of Soochow University reported on six studies. Oncology Frontier - Hematology Frontier specially invited Professor Shaoyan Hu and her team members to share their research findings on the efficacy and safety of allo-HSCT and CAR-T cell therapy in pediatric leukemia patients in a roundtable discussion format and to provide insightful commentary on these six studies.